Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism (ECHOPARAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03605472
Recruitment Status : Recruiting
First Posted : July 30, 2018
Last Update Posted : July 30, 2018
Sponsor:
Information provided by (Responsible Party):
CHU de Reims

Brief Summary:

The biological diagnosis of the primary hyperparathyroidism is now facilitated by the reliability of the balance of phosphate and calcium and the dosage of parathyroid hormone (PTH).

This diagnosis of preoperative localization is important as surgery are now targeted to the responsible lesion.

The "gold standard" for this localization is the cervical ultrasound exploring the usual sites of adenomas and a MIBI scintigraphy (the parathyroid adenoma significantly concentrating this cell marker).

However, the diagnosis of preoperative localization remains a subject of discussion as to the most appropriate tests. Indeed, the morphological diagnosis is performed at the ultrasound stage in more than half the cases. It is the new performance of this morphological examination that makes it possible to obtain these results.


Condition or disease Intervention/treatment Phase
Primary Hyperparathyroidism Other: cervical ultrasound Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism
Actual Study Start Date : October 5, 2017
Estimated Primary Completion Date : October 5, 2019
Estimated Study Completion Date : March 5, 2020


Arm Intervention/treatment
Experimental: Patients Other: cervical ultrasound
cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound




Primary Outcome Measures :
  1. Adenoma parathyroid diagnosed using cervical ultrasound [ Time Frame: Day 0 ]
    Adenoma parathyroid diagnosed using cervical ultrasound. Cervical ultrasound will be realized by a endocrinologist trained in the cervical ultrasound and not informed of the results of the echoscintigraphy

  2. Adenoma parathyroid diagnosed using echoscintigraphy [ Time Frame: Day 0 ]
    Adenoma parathyroid diagnosed using echoscintigraphy. Echoscintigraphy will be realized by a nuclear physician not informed of the results of the cervical ultrasound

  3. Adenoma parathyroid diagnosed using anatomopathology [ Time Frame: Day 0 ]
    Adenoma parathyroid diagnosed by anatomopathologist, after surgery.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with primary hyperparathyroidism with surgery indication
  • Age > 18yo

Exclusion Criteria:

  • surgical contraindication
  • medical treatment by cinacalcet
  • non sporadic hyperparathyroidism
  • Age <18yo
  • Protected by the law

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03605472


Contacts
Layout table for location contacts
Contact: Brigitte DELEMER 0326788101 bdelemer@chu-reims.fr

Locations
Layout table for location information
France
Damien JOLLY Recruiting
Reims, France
Contact: Brigitte DELEMER    0326788101 ext 0033    bdelemer@chu-reims.fr   
Sponsors and Collaborators
CHU de Reims

Layout table for additonal information
Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT03605472     History of Changes
Other Study ID Numbers: PA17094
First Posted: July 30, 2018    Key Record Dates
Last Update Posted: July 30, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by CHU de Reims:
primary hyperparathyroidism
cervical ultrasound
echoscintigraphy

Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperparathyroidism
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases